Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06452199

The BEGIN Study Bifidobacterium Infantis to Newborns: Effects of Modulating the Gut Microbial Composition on Growth, Immune Function and Inflammatory Conditions - a Randomized Placebo-controlled Double-blinded Intervention Trial

The goal of The BEGIN Study, a randomized controlled double-blinded intervention trial, is to learn if probiotics, with Bifidobacterium longum subspecies infantis Bifin02 (B. infantis), given to healthy newborns can affect various health outcomes and to explore impacts of the infant gastrointestinal microbiome. The main questions it aims to answer are:

* Does B. infantis probiotics impact immune function and does it lower the number of bacterial infections and use of antibiotics? * Does B. infantis probiotics impact overall health, development, growth and wellbeing? * Does B. infantis probiotics impact inflammatory diseases, allergies and autoimmune diseases

Researchers will compare B. infantis probiotics to a placebo (a look-alike substance that contains no probiotic) to see if B. infantis colonization impact the human immunesystem and various clinical and biochemical health markers.

Participants (parents) will

* Orally administrate the B. infantis probiotic to their newborn child daily in three weeks from 7 days of age. * Answer baseline and follow up questionnaires in a study app * Take five stool samples from the child and one stool sample from the mother * Collect a 4 week of passive dust sample at home (Electrostatic Dust fall Collector) * Donate one dried bloodspot and one blood sample from their child

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 day–7 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Regional Hospital Gødstrup, Herning, Central Jutland, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infants born at term (above gestational week 37)
  • Infants born in Region Midtjylland Denmark receiving a Danish CPR number.
  • Parents age is above 18
  • At least one parent holds a smartphone (for study app) and is able to fill out Danish questionaries
  • Both legal parents are willing and able to provide written informed consent prior to participation, regarding both themselves and their future child.

Exclusion criteria

  • Multiple pregnancy
  • Child diagnosed with immune deficiency, renal, gastrointestinal, hepatic, or endocrine diseases
  • Parents expecting to give other probiotics

Treatment and study plan

B. infantis

Dietary Supplement

1000 newborn children are randomized 50/50 to receive either B. infanits or placebo in a dietary supplement, for daily oral administration in three weeks from 7 days of age.

Other names: Bifidobacterium longum subsp. infantis Bifin02 (DSM33361)

Placebo

Dietary Supplement

Identical looking placebo (without any probiotics/B. infantis) for double-blinded daily oral administration in three weeks from 7 days of age.

Primary outcomes

  1. Prescriptions of antibiotics

    Time frame: First assessment at 1 year and up to 18 years follow-up

    Number of prescriptions of antibiotics among participants, as a measure of bacterial infections.

Secondary outcomes

  1. The intestinal microbiota and B. infantis colonization

    Time frame: 1 year

    Stool samples collected during the first year of life and tested with shutgun metagenomics, assessing the microbial composition..

  2. Antibiotic resistance genes (ARGs)

    Time frame: 1 year

    Amount of Antibiotic resistance genes (ARGs) in participants microbial community in stool samples. Identification with shutgun metagenomics. Assessing the microbial composition and diversity.

  3. Colic

    Time frame: 3 months

    Parents' observations registered in study app. Duration of crying in the first three months of life. Defined as Wessels criteria:

    Crying for three or more hours a day, three or more days a week, for three or more weeks.

  4. Bowel function, stool consistency

    Time frame: 3 months

    Parents' observations registered in study app, related to their infant child's stool consistency measured at the Infant Stool Scale

  5. Bowel function, stool frequency.

    Time frame: 3 months

    Parents' observations of their infant child's frequency of stool passings, registered in study app

  6. Bowel function, laxatives

    Time frame: 3 months

    Parents' reported use of medical laxatives for their infant child, registered in study app and reported as amount of days using the laxative.

  7. High sensitive C-reactive protein (hs-CRP)

    Time frame: 1 year

    Blood biomarker: Low-grade systemic inflammation. Unit of measurement: mg/l

  8. Cluster of Differentiation 163" (CD163)

    Time frame: 1 year

    Blood biomarker: Macrophage-mediated inflammation and insulin-sensitivity. Unit of measurement: mg/l

  9. Plasma Calprotectin

    Time frame: 1 year

    Blood biomarker: Intestinal inflammation. Unit of measurement: µg/l

  10. Allergies, Immunoglobulin E (IgE)

    Time frame: 1 year

    Blood marker: Allergies. Specific IgE against the 11 most common inhalation allergens and IgE directed against Egg white, cow's milk, codfish, wheat, peanut and soybean. Unit of measurement: IU/l

  11. Allergies

    Time frame: 1 year

    Self reported allergy symptoms

  12. Growth, weight gain

    Time frame: First assessment at 1 year and up to 18 years follow-up

    Measured as weight gain in kilograms

  13. Growth

    Time frame: First assessment at 1 year and up to 18 years follow-up

    Growth velocity and weight-for-length z-scores, measured in kilograms and centimeters and combined for Z-scores.

  14. Growth, IGF-1 (Insulin-like Growth Factor-1)

    Time frame: 1 year

    Blood biomarker: Mediating the growth-promoting effects of growth hormone. Unit of measurement: µg/l

  15. Body composition

    Time frame: 3 months

    Measured by air displacement plethysmography (ADP) (Pea Pod) estimating body fat

  16. Body composition

    Time frame: 3 months

    Measured by air displacement plethysmography (ADP) (Pea Pod) estimating muscle mass.

Other outcomes

  1. Hospital admissions

    Time frame: First assessment at 1 year and up to 18 years follow-up

    Number of hospital admissions. Registered at Landspatientregistret

  2. Febrile episodes

    Time frame: 1 year

    Number of days with a fever during the last month. A febrile episode is characterized as a body temperature at 38 degrees Celsius or above. Self-reported in a monthly questionnaire in study app.

  3. Asthma Control Test

    Time frame: 1 year, possible later follow-up

    Participants reporting symptoms of astma or astmatic bronkitis, will be asked to complete the Asthma Control Test. The scores range from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. An ACT score >19 indicates well-controlled asthma.

  4. Asthmatic Bronchitis, prescriptions

    Time frame: First assessment at 1 year

    Number of prescriptions of medicine for asthmatic bronchitis; Ventoline, Airomir, Flixotide, Aerobec, Montelukast / Singulair.

  5. Asthmatic bronchitis, hospitalization

    Time frame: First assessment at 1 year

    Number of hospitalizations due to asthmatic bronchitis.

  6. Diaper rash

    Time frame: 1 year

    Atopic skin symptoms in diaper area. Self-reported by the childs parents as affected red skin, distribution in centimeters .

  7. Rhinoconjunctivitis

    Time frame: 1 year

    Measured as Mini Rhinoconjunctivitis quality of life questionnaire Mini RQLQ, adjusted to infants. 14 questions in five domains (activity limitation, practical problems, nose symptoms, eye symptoms, and non-nose/ eye symptoms), scores for each question is ranging from 0 to 6, with 0 reflecting no affection and 6 reflecting maximum affection.

  8. Obesity

    Time frame: 18 years

    Measured as number of participants diagnosed with Obesity

  9. Metabolic syndrome

    Time frame: 18 years

    Measured as number of participants diagnosed with Metabolic syndrome

  10. Diabetes

    Time frame: 18 years

    Measured as number of participants diagnosed with Diabetes

  11. Inflammatory bowel disease

    Time frame: 18 years

    Measured as number of participants diagnosed with of Morbus Crohn and/or Colitis Ulcerosa.

  12. Dried blood spot for metabolomics

    Time frame: 3 months and 1 year

    The metabolomic method measures and compares large numbers of metabolites (for example shot chained fatty acids) present in the dried blood sample.

  13. Bloodsample analyzed with Singlecell PBMC method

    Time frame: 1 year

    Single cell sequencing is a method profiling the peripheral blood mononuclear cells (PBMC), by isolating memory B, T and B-cells

  14. Child stool sample

    Time frame: 1 year

    Stool samples collected at week 1, 4, 13, 28 and 52 will by qPCR or shutgun metagenomics examine the gut microbiome.

  15. Mother stool sample

    Time frame: 1 month

    A stool sample from the pregnant mother, preferably prior to or during birth. To analyze mothers microbial colonization, that may be transferred to the child, e.g during vaginal birth.

  16. Mother HMO-secretor status

    Time frame: 1 month

    The type of Human Milk Oligosaccharides (HMO) section in mothers' breastmilk, will be determined to exploratively study the relationship between types of HMO's, mothers HMO-secretor status and effects of B.infantis.

  17. Asthma

    Time frame: up to 18 years follow-up

    Number of participants with prescriptions of medicine for asthma

  18. Atopic disease (adjusted SCORAD grading)

    Time frame: First assessment at 1 year

    Atopic symptoms, eczema, registered in study-app with description of episodes of atopic dermatitis (adjusted SCORAD grading). Disease intensity is calculated based on six characteristics: erythema, edema, oozing/crusts, excoriations, lichenification, and dryness. Each characteristic is given a score between 0 and 3, where 0 is absent and 3 is severe. The scores for each characteristic are added together for a total intensity score of up to 18.

  19. Atopic disease, local steroids

    Time frame: First assessment at 1 year and up to 18 years follow-up

    Number of participants with prescriptions of local steroids to treat eczema.

Study contacts

Contact information is provided by the study sponsor or research team.

Marie T Philipsen, MD, PhD.stud

CONTACT

[email protected]

+45 53637369

Mia E Sjørring, MD, PhD.stud

CONTACT

[email protected]

60199810

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • Aarhus University Hospital
  • Gødstrup Hospital
  • Regionshospitalet Horsens
  • Statens Serum Institut
  • Technical University of Denmark
  • University of Copenhagen

Registry information

Official study title

The BEGIN Study Bifidobacterium Infantis to Newborns: Effects of Modulating the Gut Microbial Composition on Growth, Immune Function and Inflammatory Conditions

Acronym: BEGIN

Important dates

Study start
2024
Primary completion
2026
Study completion
2043
First posted
Jun 11, 2024
Registry last updated
Oct 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.